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U/S = Ultrasound 
DNST = Ductal carcinomas of no specific type 
ROC = Receive operating characteristic 
HER-2 = Human epidermal growth factor receptor 2 
ER = Estrogen receptor 
PR = Progesterone receptor 
ILC = Invasive lobular carcinoma 
ACR = American College of Radiology 
BCSS = Breast cancer specific survival 
LVI = Lymphovascular invasion 
Introduction 
Knowledge of prognostic factors in breast cancer allows treatment options to be 
refined by identifying which patients may benefit from adjuvant therapies. Increasing use of 
neoadjuvant therapy means that indicators of prognosis are required prior to surgery. While 
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receptor status and histological grade estimation are available from diagnostic core needle 
biopsy, information on definitive grading, sizing and nodal status is not available prior to 
excision. There is therefore a need for alternative indicators of prognosis, and imaging may 
be able to provide such information.  
 Traditionally, breast cancer prognosis is predicted based on tumour size, lymph node 
status, histological grade and the presence of lymphovascular invasion (LVI) 1. Other factors, 
including histologic tumour type 2 and molecular markers, contribute to management and 
prognostic assessment 3,4. 
 Given the increasing use of neoadjuvant chemotherapy in breast cancer patients, the 
availability of prognostic information prior to surgery is essential. Several studies have 
investigated the prognostic significance of mammographic features, identifying, for example, 
the excellent prognosis of spiculate masses smaller than 15mm 2, whereas there are 
conflicting results regarding the prognostic significance of comedo calcification 5,6.  
 Associations between ultrasound (U/S) findings and features such as histological 
grade, hormone receptor status and histological and molecular subtypes have also  been 
studied 7. Thus, there is a positive correlation between tumour size at diagnosis and 
histological grade, likely due to higher mitotic rates, and high grade tumours tend to have 
round shapes with indistinct margins 8. Lamb et al. 9 demonstrated that 36% of high-grade 
tumours show acoustic enhancement on U/S. Basal phenotype cancers are generally 
aggressive, high-grade and carry a poor prognosis 4. These tumours exhibit epithelial-
mesenchymal transition and pushing margins 10, features which correlate with lack of an 
echogenic halo at U/S 11. Triple-negative cancers have increased likelihood of early 
recurrence and distant metastases. On U/S, they have oval or round shapes with 
circumscribed margins, reflecting their rapidly proliferating nature 12,13. Calcifications are rare 
14 and they are less likely to show posterior acoustic shadowing 15. 
 However, to the best of our knowledge, there are no studies purely investigating the 
prognostic significance of U/S features. Therefore, the aim of this study was to identify 
whether U/S features of breast cancer have prognostic significance, given that they vary with 
known pathologic prognostic features. 
 
Materials and Methods  
 
Study Design 
This retrospective observational study was exempted from ethical approval review by 
the National Research Ethics Service, who waived the requirement for informed consent. The 
data was taken from a prospectively collected database, for which ethical approval was 
unnecessary as it was considered service evaluation by the Ethics committee.  
A database of all U/S lesions undergoing biopsy has been kept since April 2010.  U/S 
size and biopsy results are collected prospectively.  
A retrospective analysis was undertaken of the U/S features of all invasive cancers 
entered on the database between April 2010 and April 2012, irrespective of mode of 
treatment. Inclusion criteria included all U/S visible lesions shown to be invasive breast 
cancer at histology. Women with recurrent cancer or who had metastatic disease at 
presentation were excluded. 
Assessment was performed by an expert breast radiologist with 25 years of breast 
imaging experience, who was blinded to outcomes. 
Breast U/S was performed using Supersonic Imaging Aixplorer  U/S machine and a 
12 MHz linear array probe by consultant radiologists or specialist breast sonographers in the 




 The U/S features of the lesions were evaluated retrospectively from the recorded 
images and documented according to the American College of Radiology BI-RADS lexicon 
(fifth edition)16. Features assessed included tissue composition (homogeneous fatty, 
homogeneous fibroglandular, mixed), mass shape (oval, round, irregular), orientation 
(parallel or non-parallel), margins (circumscribed or non-circumscribed), echo pattern 
(anechoic, hyperechoic, complex cystic-solid, hypoechoic, isoechoic, heterogeneous), 
posterior effect (none, enhancement, shadowing, combined), calcifications (in a mass, 
outside a mass, intraductal or none) and associated features (distortion, duct changes, skin 
changes, focal oedema).  
Focal oedema was defined as diffuse subtle increase in echogenicity within the 
adjacent 10 – 20mm of surrounding fat. Figure 1A illustrates an example of focal oedema. 
Distal acoustic effect was classified into no posterior effect, posterior acoustic enhancement, 
posterior acoustic shadowing and combined effect. Figure 1B illustrates a case demonstrating 
posterior acoustic enhancement. Tissue composition was assigned according to the 
echotexture of the breast tissue immediately surrounding the breast tumour.  
 Skin involvement was defined as skin thickening ≥2.5mm at U/S or direct skin 
invasion. The epidermis and dermis have a normal thickness of 0.5 – 2.0mm on imaging 17. 
We considered a skin thickness of 2.5mm at U/S, which is above the normal range for normal 
skin thickness, as a cut-off value for skin thickening so that borderline cases would not be 
included as positives. Changes were further classified as skin thickening only, direct skin 
invasion or a combination of both features. Figure 2A illustrates the florid lymphovascular 
plexus located immediately beneath the skin. Figure 2B illustrates a case of skin thickening 
only overlying a breast tumour. Figure 2C illustrates an example of direct skin invasion by the 
tumour. 
 For analysis purposes, tumour size was treated as a continuous variable and analysed 
using Receiver Operating Characteristic (ROC) curves. For illustrative purposes only, U/S 
tumour size was divided into three groups; ≤ 10.00mm, > 10.01 – 20.00mm and > 20.00mm. 
 
 Patient survival and cause of death were ascertained from local and national 
computer records. Patient who died with metastatic disease were assumed to have died 
from metastatic breast cancer. 
 
Statistical Analysis 
Statistical analysis of categoric variables was carried out using Kaplan-Meier survival curves. 
Statistical significance was tested using the Log-Rank test. Survival according to U/S size was 
assessed using receiver operating characteristic (ROC) curves and by Kaplan-Meier survival 
curves of grouped data. Multivariate analysis of factors that were significant at univariate 
analysis was carried out using the Cox Regression analysis.  
 All statistical analyses were carried out by using MedCalc Statistical Software version 
16.4.3 (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2016) and p < 




Patient Characteristics and Descriptive Data 
Four patients with recurrent breast cancer and 10 patients with metastatic disease at 
presentation were excluded from the study. Thus, the final study group consisted of a total of 
319 consecutive patients with 335 breast cancer lesions, of which 209 (62%) were 
symptomatic and 126 (38%) had screen-detected cancers. Two patients had bilateral breast 
cancers and 6 had multifocal lesions (2 lesions) in the same breast. U/S visible lesions 
detected on second-look U/S following Magnetic Resonance Imaging (MRI) were not 
included. None of the patients with multifocal lesions or bilateral breast cancers died. Patient 
age ranged from 36 – 95 years (mean age of 63 years).  
There were 30 breast cancer deaths and 45 non-breast cancer deaths in the cohort. 
The mean follow-up in those alive, at the time of ascertainment, was 80.9 months. Two 
hundred and seventy-six patients (82.3%) were managed by primary surgery, 29 patients 
(8.7%) received neoadjuvant chemotherapy, 9 patients (2.7%) received neoadjuvant 
endocrine therapy and 21 patients (6.3%) were managed with primary endocrine therapy. 
 
Ultrasound and Histological Characteristics 
 At histology, 36 (10.7%) were grade 1 tumours, 144 (43.0%) were grade 2 and 155 
(46.3%) were grade 3 tumours. Table 1 describes the pathological and molecular 
characteristics of the study sample in relation to the number of breast cancer deaths in each 
sub-group. Table 2 describes the frequency of U/S features in relation to the number of 
breast cancer deaths in each sub-group. Twenty-three of the 30 breast cancer deaths (77%) 
occurred in Grade III tumours. Seventeen of the 30 breast cancer deaths (57%) occurred in 
patients who were treated by primary surgery, all of whom had tumours greater than or 
equal to 15mm in size. 
 
Ultrasound Characteristics and Breast Cancer Specific Survival 
 At univariate analysis, large U/S tumour size, the presence of skin involvement (skin 
thickening and/or direct invasion), focal oedema and the presence of distal acoustic 
enhancement were all associated with poorer breast cancer specific survival (BCSS). 
 Using ROC analysis, the area under the curve was 0.72. This is depicted in figure 3A, (p 
= < 0.0001). This is illustrated by the Kaplan Meier survival curve (figure 3B) which shows that 
patients with an U/S tumour size between 10.01 - 20mm were twice as likely to die from 
breast cancer, and patients with an U/S tumour size > 20mm were eight times more likely to 
die from breast cancer as compared to those with an U/S tumour size ≤ 10.00mm. 
 Distal acoustic enhancement was associated with a 76% 5-year BCSS compared to 
88%, 96% and 100% BCSS for those with distal shadowing, no distal effect or combined effect 
respectively (p = 0.0002) (Figure 4). Twelve breast cancer deaths occurred in the 56 tumours 
(21%) demonstrating distal acoustic enhancement as compared to a 3% breast cancer death 
rate in tumours showing no distal acoustic effect, an 8% breast cancer death rate in tumours 
showing posterior acoustic shadowing and a 0% breast cancer death rate in tumours showing 
a combined posterior effect. 
 Skin involvement (skin thickening over the mass and/or direct invasion) was 
associated with a 73% 5-year BCSS compared to 92% in women without skin involvement (p = 
< 0.0001) (Figure 5). In fact, 13 breast cancer deaths occurred in the 56 tumours (23%) with 
skin changes as compared to a 6% breast cancer death rate in tumours without skin 
involvement. 
 Although skin involvement was detected by U/S in 56 (16.7%) patients, clinical dermal 
involvement was documented in only 14 (4.2%) cases (skin oedema = 7, skin ulceration = 3, 
lesions tethered to the skin = 4), in whom 3 breast cancer deaths occurred. In the 42 cases 
with non-clinically apparent skin involvement, 10 breast cancer deaths occurred. Therefore, 
the vast majority of breast cancer deaths in this patient sub-group occurred in patients 
without clinical skin involvement. When looking at the type of skin involvement (skin 
thickening only, direct invasion only and combined type), the number of patients in each 
group was too small for subgroup analysis. 
 Focal oedema was associated with a 56% 5-year BCSS compared to 89% in women 
without associated oedema (p = 0.0002) (Figure 6). Four breast cancer deaths occurred in the 
12 lesions (33%) that demonstrated focal oedema on U/S as compared to a 6% breast cancer 
death rate associated with lesions not associated with focal oedema. Six of the cases with 
focal oedema (50%) also had associated skin thickening. 
 The overall BI-RADS assessment category was of borderline significance (p = 0.0538) 
with tumours in category 5 having an 83% 5-year BCSS compared to tumours in category 3 
and category 4 having a 100% and a 94% 5-year BCSS respectively. The presence of 
calcifications within the mass was not significant (p = 0.0918). None of the tumours in the 
cohort showed U/S evidence of calcifications outside a mass or within the ducts. 
 Mass shape, echogenicity, margin characteristics, orientation and duct changes on 
U/S were not significant at univariate analysis.  
 At multivariate analysis of factors that were significant at univariate analysis, skin 
involvement, posterior acoustic enhancement and focal oedema maintained prognostic 
significance. U/S tumour size lost significance. Table 3 depicts the final model of stepwise 
multivariate analysis for BCSS. 
 Analysis of sub-groups according to immunophenotype could not be done due to the 
small number of breast cancer deaths. 
 
Discussion  
 The established prognostic factors for invasive breast cancer are lymph node stage, 
histological grade, histological size and LVI. In addition, the presence of specific molecular 
markers, such as ER and HER2, patient age and mode of presentation provide additional 
prognostic information. Our underlying hypothesis was that the U/S features of breast cancer 
have prognostic significance, which can be used to guide the use of neoadjuvant systemic 
treatment.  
 Our study demonstrates that skin involvement, posterior acoustic enhancement and 
focal oedema on U/S are strongly and independently associated with poor breast cancer 
specific survival in women with invasive breast cancer.  
 The poor outcome associated with skin involvement at U/S is likely related to the 
presence of a rich vascular and lymphatic plexus beneath the skin. The presence of LVI is a 
recognised poor prognostic factor in a wide range of tumour types, including breast cancer 
and malignant melanoma, both of which exhibit a strong tendency to lymphatic spread 18. 
 Distant metastases are the cause of most deaths in primary cutaneous melanoma 19. 
LVI is considered a sign of aggressive disease that leads to regional lymph node and distant 
metastasis, with a positive lymphatic invasion status being an unfavourable prognostic factor 
even in patients without regional lymph node metastases 20–26. Tas et al. 21 demonstrated 
that LVI has significant prognostic impact on nodal involvement, recurrence and overall 
survival in cutaneous melanoma.  
 Similarly, several studies 27,28 have shown LVI in breast cancer  to be an adverse 
prognostic marker even in patients with node-negative disease.  
 Therefore, we hypothesise that skin involvement at U/S results in invasion of the 
cutaneous lymphovascular plexus in a mechanism similar to that of malignant melanoma. 
This would explain the prognostic significance of both skin involvement and focal oedema at 
ultrasound. In fact, disease processes that result in breast oedema, such as tumour in the 
breast dermal lymphatics and congestive heart failure, are typically associated with skin 
thickening 29,30. 
 Interestingly, three studies have shown that tumour-to-skin distance is an 
independent predictor of axillary lymph node metastasis in breast cancer 31–33. Breast cancers 
located closer to the skin were found to have a higher incidence of axillary nodal metastasis, 
even in patients with clinically node-negative early-stage disease. However, none of these 
studies investigated the association with breast cancer mortality. 
 Given the strong association between skin involvement and breast cancer mortality in 
our study, and given the fact that the vast majority of breast cancer deaths in this patient 
sub-group occurred in patients without clinical skin involvement, the routine reporting of the 
skin overlying the tumour on breast U/S examinations should be considered.  
 The association between posterior acoustic enhancement and poor BCSS can be 
explained by the known relationship between posterior acoustic enhancement and high 
pathologic grade. In this study, the majority of tumours demonstrating posterior acoustic 
enhancement were high grade. Lamb et al. 9 showed that high-grade invasive cancers were 
more likely to demonstrate posterior acoustic enhancement. A further study by Rotstein et 
al. 34 showed that Grade 3 invasive ductal carcinoma is more likely to cause posterior 
enhancement or posterior isoechogenicity than posterior shadowing. It has been suggested 
that tumours which demonstrate posterior enhancement are more cellular 35,36 and that it is 
the organisation rather than the absolute amount of fibrous tissue that determines tumour 
attenuation characteristics 37. Tumours that demonstrate acoustic enhancement have 
decreased desmoplasia 36-38. Therefore, the prognostic significance of this U/S feature was 
not unexpected. 
 In this study, U/S size was a significant prognostic factor in univariate but not in 
multivariate analysis. Tumour size is a time-dependent prognostic factor, which has been 
shown in many studies to influence outcome 39. However, its significance is minor once nodal 
stage and pathologic grade are taken into account.  
Survival of breast cancer is obviously dependent on the treatment received, 
particularly systemic therapy. The type and benefit of systemic therapy are molecular 
subtype dependent but unfortunately our study is too small to allow such analysis to be 
performed.  
 Limitations of this study include the relatively small sample size from a single centre. 
Images were reviewed by one consultant radiologist, so the question of reproducibility of U/S 
features has not been addressed. Consistency of reporting of distal effect may be variable, as 
some lesions had a mixed pattern. Measuring skin thickness was easier and more likely to be 
highly repeatable. U/S features were documented by retrospective review, even though most 
data was acquired prospectively, and therefore further image optimisation was not possible. 
The small percentage of invasive cancers that are not visible on ultrasound are obviously not 
included in our study. These lesions are, however, usually small and unlikely to lead to breast 
cancer death. Sub-analysis by molecular subtype would have been interesting, but the small 
number of breast cancer deaths in each group would have made it impractical.  
 In conclusion, we have found focal oedema, skin involvement and posterior 
enhancement on U/S to be strongly associated with BCSS in an unselected breast cancer 
population. Only 25% of those with U/S detected skin involvement had clinical skin 
involvement. We hypothesise that skin involvement leads to invasion of the rich subdermal 
plexus of lymphatics and veins leading to systemic spread. The effect of posterior acoustic 
enhancement on mortality is most likely due to its association with high-grade tumours. 
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Table 1: Pathological and molecular characteristics of our study population. 
*Denominators for invasive size, lymph node status and vascular invasion are fewer 
than 335 due to women receiving neoadjuvant and primary systemic therapy. Size, 
vascular invasion and nodal positivity is only reported in those undergoing immediate 
surgical management. 
*One patient undergoing immediate operative treatment did not undergo lymph node 
dissection because of comorbidities. 
+HER2 results were not available in 4 cases. 
DNST = Ductal carcinoma of no specific type 
 














































































































































Associated features – Duct changes 
Duct changes 










































Table 2: Frequency of the ultrasound features in our study population. 
*In our study, calcifications were only demonstrated within the mass. 
 
Feature B SE Wald P Exp(b) 95% CI of 
Exp(b) 




1.1425 0.3810 8.9936 0.0027 3.1346 1.4856 to 
6.6140 
Skin changes 1.2757 0.3794 11.304
6 
0.0008 3.5813 1.7024 to 
7.5340 
 
Table 3: Final model of stepwise multivariate analysis for Breast Cancer Specific Survival 
(BCSS). Data are for all cases and include focal oedema, posterior acoustic enhancement and 
skin changes versus other radiological features. 
Exp(b) = The exponential of the b coefficient 
SE = Standard error 
 
